Anti-interleukin 4 and 13 for asthma treatment in the era of endotypes

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Current Opinion in Allergy and Clinical Immunology

• Publication date

  2014-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/ACI.0000000000000108PMID 25144263PMCID PMC4374802
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

  2014cited by this paper
• Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial.

  2014cited by this paper
• Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids.

  2013cited by this paper
• Converging Discoveries: The First Reports of IL-4

  2013cited by this paper
• Dupilumab in persistent asthma with elevated eosinophil levels

  2013cited by this paper
• The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge

  2013cited by this paper
• A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics.

  2013cited by this paper
• Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.

  2013cited by this paper
• Development of a Human IgG4 Bispecific Antibody for Dual Targeting of Interleukin-4 (IL-4) and Interleukin-13 (IL-13) Cytokines*

  2013cited by this paper
• A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

  2012cited by this paper
• Asthma phenotypes: the evolution from clinical to molecular approaches

  2012cited by this paper
• Therapies for allergic inflammation: refining strategies to induce tolerance

  2012cited by this paper
• US and European severe asthma cohorts: what can they teach us about severe asthma?

  2012cited by this paper
• IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist.

  2012cited by this paper
• Lebrikizumab treatment in adults with asthma.

  2011cited by this paper
• Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome.

  2011cited by this paper
• Novel therapeutic approaches for pulmonary fibrosis

  2011cited by this paper
• Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients.

  2011cited by this paper
• Predictive and Pharmacodynamic Biomarkers of Interleukin-13 Blockade: Effect of Lebrikizumab on Late Phase Asthmatic Response to Allergen Challenge

  2011cited by this paper
• Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma.

  2011cited by this paper
• Current prospective of anti-IL-4, -IL-9, and -IL-13 therapies in allergic disease.

  2010cited by this paper
• A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma.

  2010cited by this paper
• IL-4 receptor α polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist.

  2010cited by this paper
• Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids

  2007cited by this paper
• Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies.

  2007cited by this paper
• Level of Expression of IL-13Rα2 Impacts Receptor Distribution and IL-13 Signaling1

  2006cited by this paper
• Level of expression of IL-13R alpha 2 impacts receptor distribution and IL-13 signaling.

  2006cited by this paper
• Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.

  2004cited by this paper
• Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti‐interleukin‐4 antibody with therapeutic potential in asthma

  2002cited by this paper
• Efficacy of soluble IL-4 receptor for the treatment of adults with asthma.

  2001cited by this paper

• Glucocorticoid Insensitivity in Severe Asthma: Underlying Molecular Mechanisms, Challenges, and Emerging Therapies

  2025cites this paper
• Role of the Th2-like Immune Response in Obesity: IL-4 as a Metabolic Regulator and IL-13 as an Effector of Muscle Energy Metabolism

  2025cites this paper
• Mitochondria targeted hydrogen sulfide donor AP39 attenuates allergic airway inflammation and airway hyperreactivity in mouse.

  2025cites this paper
• Role of interleukin-4 receptor α polymorphism in patients with asthma and its correlation with asthma severity.

  2025cites this paper
• Learning multi-cellular representations of single-cell transcriptomics data enables characterization of patient-level disease states

  2025cites this paper
• The role of Interleukin-21 (IL-21) in allergic disorders: Biological insights and regulatory mechanisms.

  2024cites this paper
• Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways

  2024cites this paper
• Asthma-COPD Overlap in Clinical Practice (ACO_CP 2023): Toward Precision Medicine

  2023cites this paper
• Airway Epithelial-Derived Immune Mediators in COVID-19

  2023cites this paper
• New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis

  2023cites this paper
• Targeting IgE and Th2-Cytokines in Allergy: Brief Updates on Monoclonal Antibodies and Antibody Gene Therapy

  2023cites this paper
• The Role of Defective Epithelial Barriers in Allergic Lung Disease and Asthma Development

  2022cites this paper
• Comprehensive analysis of human IL‐4 receptor subunits shows compartmentalization in steady state and dupilumab treatment

  2022cites this paper
• Precision Medicine

  2022cites this paper
• Novel Lung Growth Strategy with Biological Therapy Targeting Airway Remodeling in Childhood Bronchial Asthma

  2022cites this paper
• Diagnosis and management of asthma in children

  2022cites this paper
• The Effect of Unconventional Cytokine Combinations on NK-Cell Responses to Viral Infection

  2021cites this paper
• A critical regulation of Th2 cell responses by RORα in allergic asthma

  2020cites this paper
• Asthma Biologics: Comparing Trial Designs, Patient Cohorts and Study Results.

  2020cites this paper
• Practical Approaches in M2 Macrophage Biology: Analysis, Pharmacology, and Didactical Interpretation of M2 Macrophage Functions

  2020cites this paper
• Anti-IL-4/IL-13 for the treatment of asthma: the story so far

  2020cites this paper
• Can early intervention in pediatric asthma improve long‐term outcomes? A question that needs an answer

  2019cites this paper
• On the Move: The Commander IL-4 Leads the Cell Army in Collective Migration

  2019cites this paper
• Nasal Cytokine Profiles of Patients Hospitalised with Respiratory Wheeze Associated with Rhinovirus C

  2019cites this paper
• Биологическая терапия тяжелой астмы: новые цели и новые возможности лечения

  2019cites this paper
• Biological treatment of severe asthma: new objectives and new treatment options

  2019cites this paper
• Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions

  2018cites this paper
• Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for children and adults with asthma

  2018cites this paper
• Efficacy of an Inhaled IL‐13 Antibody Fragment in a Model of Chronic Asthma

  2018cites this paper
• Revisiting asthma therapeutics: focus on WNT signal transduction.

  2018cites this paper
• Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD.

  2018cites this paper
• RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study

  2017cites this paper
• Immune monitoring for precision medicine in allergy and asthma.

  2017cites this paper
• Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches

  2017cites this paper
• Biological Therapies of Immunologic Diseases: Strategies for Immunologic Interventions.

  2017cites this paper
• Allergies - A T cells perspective in the era beyond the TH1/TH2 paradigm.

  2017cites this paper
• Bifunctional Drugs for the Treatment of Respiratory Diseases.

  2017cites this paper
• WNT and β-catenin signalling in airway smooth muscle: emerging concepts for asthma

  2017cites this paper
• Point-of-care blood eosinophil count in a severe asthma clinic setting.

  2017cites this paper
• Relationship of Allergy with Asthma: There Are More Than the Allergy “Eggs” in the Asthma “Basket”

  2017cites this paper
• Tissue Remodeling in Chronic Eosinophilic Esophageal Inflammation: Parallels in Asthma and Therapeutic Perspectives

  2017cites this paper
• Hyperpolarized Gas MRI of the Lung in Asthma

  2017cites this paper
• The contribution of T cell-derived cytokines and proteases to chronic inflammation in the human intestine

  2016cites this paper
• Suppressor of Cytokine Signaling (SOCS)1 Regulates Interleukin-4 (IL-4)-activated Insulin Receptor Substrate (IRS)-2 Tyrosine Phosphorylation in Monocytes and Macrophages via the Proteasome*

  2016cites this paper
• From IgE to Omalizumab

  2016cites this paper
• Asthma phenotypes and endotypes: a personalized approach to treatment

  2016cites this paper
• Toward precision medicine and health: Opportunities and challenges in allergic diseases.

  2016cites this paper
• Viruses and bacteria in Th2‐biased allergic airway disease

  2016cites this paper
• Effect of BCG-PSN adjuvant therapy on Th 1 / Th 2 immune response in bronchial asthma children

  2016cites this paper
• Correlation between pro-inflammatory alleles and clinical and laboratory markers of allergy in Xhosa South Africans

  2016cites this paper
• University of Groningen Farming exposure and asthma phenotypes

  2015cites this paper
• Evaluating results of outcome studies of biological drugs.

  2015cites this paper